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Abstract
Advancement in technology is continued as the time is passed. The biological 
active ingredients technology is the challenging issues for both the researchers and 
manufacturers. In last decade, much research has been happened about the poten-
tial health benefits of pro and prebiotic ingredients. Probiotics are the live microor-
ganisms when given in adequate amount confer health benefits but the prebiotics 
are indigestible ingredients that enhance the activity of one or more probiotics in 
the colon. The therapeutic potential of these two biological active ingredients is the 
outcome of emerging field of biotechnology. A number of studies indicating thera-
peutic potential of probiotics regarding gastrointestinal health, cancer, constipa-
tion, immunomodulation, Helicobacter pylori, liver disease and urogenital infection 
have been documented. Similarly, prebiotics also improved helpful for many 
communicable and non-communicable diseases. It can be seen that advancement in 
the biotechnology field offer great choice to deliver a marvelous health advantages. 
Although the market for probiotic and prebiotic food and supplements has been 
increased in this new era but still need to develop food and supplements containing 
these two active ingredients with the cooperation of legal bodies of the country.
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1. Introduction
This chapter criticizes and presents the role of different probiotics and prebiotics 
in the prevention of various ailments and improvement of consumer’s health. Scientist 
worked and explored the action of beneficial live microorganisms and non-digestible 
food components for the improvement of human health. The chapter highlights various 
sources and mode of action of probiotics and prebiotics. Disease prevention and health 
intriguing aspects of these therapeutic components is also addressed in this chapter.
2. Probiotics
The term probiotics was characterized by Parker [1] as life forms and some sub-
stances which are responsible for the equalization of the intestinal microorganisms. 
Fuller [2] defined probiotics as feed supplements in the form of live microorgan-
isms which valuably influences the host creature by enhancing the microbial bal-
ance in the intestines. Subsequently, Moriarty [3] recommended that the meaning 
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of probiotics be reached out to microbial water added substances. Administering 
probiotics in water has been appeared to enhance water quality by decreasing the 
centralizations of nitrogen and phosphorus [4]. Probiotics directed in water or 
eating routine likewise may hinder the development of pathogenic microorganisms, 
contribute stomach related proteins to expand feed usage, give other development 
advancing components, and restoring the immune response of the living beings.
Hill et al. [5] updated the probiotics as live microorganisms when given in 
adequate amount confer health benefits.
2.1 Probiotics: selection criteria
For the living organisms to be termed as probiotics the given criteria should be 
fulfilled:
1. It must get separated from the same species from its expected host.
2. It ought to have an clear favorable impact on its host.
3. It should not produce any symptoms of disease.
4. It ought to have the capacity to survive the conditions gastrointestinal tract and 
can easily be passed through it.
5. During storage, greater number of practical microscopic organisms must have 
the capacity to endure extended lengths of time [6, 7].
2.2 Probiotics: mechanism of action
Mechanisms for the advantages of probiotics are not completely understood. 
However, generally it includes [8].
• Adherence and colonization of the gut.
• Suppression of development or epithelial authoritative/intrusion by pathogenic 
microscopic organisms and generation of antimicrobial substances.
• Improvement of intestinal hindrance work.
• Controlled exchange of dietary antigens.
• Stimulation of host mucosal and systematic immunity [9].
2.3 Standardization of probiotics
In Europe health claims of probiotics are assessed by the “European Food Safety 
Authority” (EFSA). For the selection guidance of probiotics European Commission 
published probiotics health claims [10] this meant that probiotics are not consid-
ered as nutrition claim but it is a health claim. It is further clarified that this general 
health claim is not mention for any body functions because the health claim of 
probiotics and strain specific. Consequently, probiotics term is banned with regard 
to advertising and labelling as food supplement in Europe.
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In USA probiotic companies face legal encounters. In the research of probiotics, there 
are also FDA’s restrictions for human trials. The study with regard to human trial must 
be filed as “Investigative New Drug,” which appears redundant and costly obligation.
In Canada, the government has also issued regulatory documents for the use 
probiotics in food. Canada has a list of 17 probiotic species that can make nonspe-
cific health claims, but no strain-specific probiotic claims have been approved [11].
In 2012, the Chinese Food and Drug Administration (CFDA) issued 
“Requirements on and a Guide to the Naming of Health Foods” and this year, 
provision for health food registration and filing was released. Currently, there are 
27 health food categories based on health effects recognized in China, including 
enhancing immunity, the maintenance and relief of constipation, and modulating 
the intestinal bacteria. The health claim of any probiotics are governed an approval 
process involving technical review of safety, scientific substantiation of the health 
effect (based on animal and/or human studies), quality control, quantitative assess-
ment and assessment of the product formulation [12].
2.4 Commonly used probiotics
A portion of the widely utilized probiotic microorganisms are Lactobacillus 
rhamnosus, Lactobacillus reuteri, bifidobacteria and certain strains of Lactobacillus 
casei, Lactobacillus acidophilus-groups, Bacillus coagulans, Escherichia coli strain 
Nissle 1917, certain enterococci, particularly Enterococcus faecium (SF68), and the 
yeast Saccharomyces boulardii. Bacterial spore formers, for the most part of the class 
Bacillus influence the scene. The given probiotics are being used in variety of food 
products such as fermented milks either independently or in mixes. With the new 
research endeavors new genera and strains of probiotics are being developed.
Probiotic can either include a single stain or a blend of at least two strains. For 
example, VSL3 is a probiotic that comprises of blend of eight different strains. The 
effects of probiotics are strain specific and cannot be summed up. A one strain may 
display diverse advantages when utilized exclusively and in mix. The benefits aris-
ing from the use of probiotics vary according to patient group. Constrained studies 
showed the adequacy of use of multiple probiotic strains [13].
FAO and WHO have mutually introduced advanced rules with a specific end 
goal to establish the systematic outlook for a successful Probiotic assessment 
probiotics in nourishments to support the health cases and other advantages. The 
standard rules on probiotics developed by FAO/WHO could be used worldwide for 
assessing probiotics in nourishment that can lead to the supporting of health claims. 
According to the rules following activities must be fulfilled:
1. Identification of strain.
2. Functional portrayal of the strains and safety properties.
3. Proving the medical advantages in human examinations.
4. Labeling of the adequacy claims and the shelf life of the substance must be 
honest and should not be deceiving.
2.5 Therapeutic potential of probiotics
The probiotics have most imperative and recorded helpful impacts that incor-
porate the prevention from various diseases including diarrhea, increasing the 
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effectiveness of antibacterial activity, reduction in the symptoms of constipation, 
changes in the conjugation of bile and salts. Moreover, they are also involved in 
nutrient formation and in enhancing their utilization by the body; a few probiotics 
are thought to have anti-oxidant action as entire cells or lysates. Probiotics have 
additionally exhibited their intrinsic impacts in reducing manifestations of allergy, 
cancer AIDS, various infections of respiratory system and urinary tract. There are 
different random reports on their advantageous impacts on autism, fatigue, type 2 
diabetes, aging, fatigue, obesity and osteoporosis [14].
2.5.1 Diarrhea
The Diarrhea is defined by World health Organization as three to four watery 
stools in the period of 24 hours. Over the period of more than 20 years several 
examinations have been done on the microorganisms by several in vitro studies, 
animal models and some other suitable clinical investigations have confirmed 
the role of probiotics in reducing the severity of various type of diarrhea [15] 
Saccharomyces boulardii is the only yeast probiotic that is used for treating the 
diarrhea.
2.5.1.1 Acute infantile diarrhea
Rotavirus is the major cause of acute infantile diarrhea and is the most con-
centrated gastrointestinal condition and it requires quick oral rehydration as 
an essential treatment. Along with the oral rehydration therapy Probiotics are 
thought to have beneficial effects. Although further data is needed to confirm the 
investigations however 10 billion CFU is the minimum potent dose in kids within 
the 48 hours [16]. A trial was conducted on C. difficile-related colitis and results 
showed that S. boulardii reduce the onset of infection in the patients who had more 
than one consecutive C. defficile disease. S. boulardii is yeast which produces prote-
ases that inhibit the C. defficile toxins and also blocks its receptors in the intestines. 
The yeast S. boulardii discharges a protease that separates C. difficile poisons and 
hinders the poison intestinal receptors. The Probiotic additionally found to activate 
particular antitoxin A which is an immunoglobulin that attacks the factor involved 
in increasing the risk of diarrhea [17, 18].
2.5.1.2 Antibiotic associated diarrhea
Disruption of the natural micro flora is due to the use of anti-microbial medica-
tions, i.e., antibiotics frequently prompts diarrhea. The principle component by 
which antimicrobials cause loose bowels is through weakened protection against 
pathogens because of disruption of gut micro flora and as a result there is a modi-
fication in the digestion of sugars bile acids and unsaturated fatty acids resulting 
modifications in the digestion of sugars, short-chain unsaturated fats, and bile acids 
[19]. Probiotics are more powerful in reducing the onset of diarrhea as a result of 
use of antibiotic medications and these includes strains of L. acidophilus, yeast S. 
boulardii, L. delbrueckii, L. rhamnosus GG, L. fermentum, etc. [18]. However, further 
studies are needed to confirm the beneficial role of probiotics in various diseases, 
which probiotic is more potent and their recommended dosages [20].
2.5.1.3 Traveler’s diarrhea
It has been assessed that around 20–60% of the people traveling around the 
world are affected by this type of diarrhea. It especially influences individuals those 
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who travel from the developed or industrialized areas to the backward or remote 
areas, specifically traveling between tropical regions and other non-tropical areas. 
The major cases that are recognized are due to the microscopic organisms which 
accounts for approximately 60–85% of the cases and most causative bacteria for 
causing this is E. coli and Compylobacter jejuni and some other species of Salmonella 
and Shigella disease is also caused by parasites and viruses which accounts for 
around 10% and 5% toward causing the infection [21]. It was observed that the bac-
teria that was effective against Bacterial diarrhea is S. boulardii whereas the activity 
of Lactobacillus GG was observed to be more potent against diarrhea caused by the 
virus and the idiopathic diarrhea [22–24]. Bacterial Strains that are thought to have 
preventive effect on the traveler’s diarrhea include the Bifidobacteria, Lactobacilli, 
and Streptococci and Enterococci [18].
2.5.2 Inflammatory bowel disorder (IBD)
IBD is a long term degenerative disease which involves the severe irritation of G.I.T 
tract that leads of watery and bloody diarrhea along with the abdominal pain IBD 
affects the small intestines and a portion of large intestines that is colon and it includes 
three different conditions which are Crohn’s disease, ulcerative colitis (UC) and pou-
chitis. The other factors that are associated with the onset of disease include the genetic 
factors, ecological factors, oxidative stress and the weakened immune system [25].
Crohn’s disease and ulcerative colitis are long term diseases of the gastro-intes-
tinal tracts that are associated with the inflammation of the immune and likely are 
because there is absence of balance of the natural immunity with the surroundings 
and the with the advancement of the culture [26]. Intake of probiotic bacteria can 
possibly balance out the immunological boundary in the gut mucosa by diminish-
ing the production of nearby proinflammatory cytokines [27–29]. Bifidobacterium 
infantis 35,624 helps in elevating the symptoms of abdominal pain, bloating, passage 
of gas, straining, bowel dysfunction and incomplete evacuation in the patients of 
IBD. It has been observed through recent studies that Probiotic supplementation is 
very helpful in elevating the symptoms of IBD and in some cases even the medical 
therapy can be replaced by probiotic supplementation. However it is not recom-
mended for the Crohn’s disease as the data does not support the use of probiotics. 
Therefore Probiotics have shown promising role in reducing the symptoms of 
ulcerative colitis but not in the case of Crohn’s disease [30].
2.5.3 Ulcerative colitis (UC)
Ulcerative colitis like Irritable bowel disorder fundamentally influences the 
inner layer of the rectum and that of large intestines. Long-term ulcerative colitis 
can lead to the development of colon cancer. Use of different probiotics including 
S. boulardii, L. casei, Bifidobacterium bifidum has demonstrated beneficial results in 
terms of this disease [31]. A Study was conducted and the results demonstrated that 
the addition of probiotics bacterial strains of L. acidophilus, B. bifidum, and B. breve 
in the fermented milks was helpful in mitigating the diseases in patients [32].
2.5.4 Crohn’s disease (CD)
It is a type of Irritable bowel syndrome which ordinarily influences the digestive 
system; however it may affect any organ from the mouth to the end of the end of 
digestive tract. Crohn’s disease leads to the development of the ulcers and irrita-
tion that influences the capacity of the body to process food, assimilate nutrients 
and excretion of unwanted products in a healthful form. The Bacterial strains that 
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are involved in causing Crohn’s disease include Salmonella, Clostridium difficile, 
Campylobacter jejuni, Mycoplasma and Adenovirus, There are various reports that 
influence the efficacy of various probiotics, e.g., S. boulardii, L. GG, VSL3, E. coli 
Nissel 1917, in combating the issues of CD in human beings [33].
The role of probiotics in therapeutic utilization of Crohn’s disease is because of 
its competition with the groups of bacteria, maintaining the immune system and 
also destroying the various pathogenic microorganisms. Irritable bowel syndrome 
can additionally be prevented by using the probiotics which help in maintaining the 
defensive functions of the mucosa of intestines [34].
2.5.5 Pouchitis
Pouchitis is third kind of Irritable bowel syndrome where there is inflammation 
of ileal pouch particularly after the procedures such as colectomy and the other 
include anastomosis of ileal pouch. Various Studies were done and it was observed 
that the blend of probiotic VSL3 plays a significant role in the reduction of this 
disease [35].
The strains of powerful probiotic stimulate definite IL-10 and IL-4 mucosal cyto-
kine. Also Probiotics may impact the cell to cell association of mucosa and integrity 
of the cells through upgrading activity of intestinal mucosa through the regulation 
of phosphorylation and cytoskeletal activity of tight junctional protein and further-
more through the production of enzymes having anti-oxidant nature. For example, 
catalase and superoxide dismutase hence remediating the symptoms of IBD [36].
Ileal pouch-anal anastomosis (IPAA) is the favored option to proctocolectomy 
with perpetual ileostomy in ulcerative colitis and the inherited disease in which 
adenomatous polyps are formed in the epithelial of large intestines. The most as 
often as possible noticed chronic problem of IPAA is potentially perpetual inflam-
mation of the ileal supply which is either acute or chronic and is called pouchitis. 
Gionchetti et al. in a randomized, controlled treatment containing placebo pre-
liminary in which VSL3 was regulated to 40 patients quickly after carefully surgi-
cal formation of ileal anal pouches, accomplished abeyance of 90% in the group 
treated with VSL3 versus 60% in the placebo treatment group following a year 
[37]. These examinations have confirmed the role of VSL3 in the administration of 
pouchitis [38].
According to the Rome II Crieteria irritable bowel syndrome is defined as 
syndrome that lasts for greater than 3 months with the implications of either 
diarrhea or constipation and also accompanied by the abdominal pain. Many 
studies on the role of probiotics in preventing Irritable bowel syndrome have 
been conducted [39–43]. Out of five surveys conducted three trials showed 
a decrease trend in the symptoms of Irritable Bowel Syndrome. As there is a 
beneficial role of the probiotics but the reduction in the symptoms of disease 
without the clinical manifestations has not yet confirmed. However, beneficial 
role of probiotics in terms of clinical improvement can be attained in reduc-
ing the symptoms related to the diarrhea. Many new studies are needed to be 
conducted on variety of bacterial strains to draw any conclusion regarding their 
beneficial role [44].
2.5.6 Lactose intolerance
It is a type of disorder that comprises of intolerance to the digestion of carbohy-
drate lactose that is present mainly in dairy products having prevalence of around 
7–20% in Caucasians, 90–100% in Asians and from around 50–85% in Africans 
[45]. Lactose intolerance can be solved by using the probiotics that alleviate 
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the symptoms by reducing the transit time through gastro-intestinal tract [46]. 
Probiotics such as Streptococcus thermophilus and Lactobacillus bulgaricus undergo 
the process of fermentation and as a result produces an enzyme lactase that helps in 
the breakdown of lactose into its subunit glucose and galactose. Thus, it is suggested 
that the intake of probiotics can help in the digestion of lactose inside the gut lumen 
and reducing the symptoms of lactose intolerance in both children and adults [47].
2.5.7 Colon cancer
The intake of probiotics and prebiotics has several antagonistic effects on muta-
gens [48, 49]. The link between the colon cancer and diets that are high in fats and 
oils and low in fiber and some other western diets lead to the alteration in the bacte-
rial enzymes in the feces. The process through which the probiotic bacteria such as 
lactobacilli reduce the onset of colon cancer may include various modifications on 
the metabolic pathways of the intestinal microflora, inhibiting and binding of the 
cancer causing agents, physicochemical alterations in binding to colon, formation 
of compounds cancer causing agents and several other mutagens. Improving the 
immune system and physiology of the host. There is a remarkable evidence on the 
basis of various animal models and controlled studies [50, 51]. However, there is not 
enough data or studies to confirm the role of probiotics for protection against the 
onset of colon cancer.
The process through which the probiotics exhibit tumor suppressing activity 
includes the modification in the immune functions that are related with the vari-
ous immune responses, Regulating cell differentiation and apoptosis, inhibiting 
the formation of the enzymes produced from the pathogenic bacteria E. coli and C. 
perferinges that includes the ureases different reductases specifically nitroreductases 
and oxidoreductases, β-glucuronidase and choloylglycine hydrolase. Enzymes such 
as ureases and beta glucosidases are involved in the conversion of pro carcinogens to 
the active carcinogens. In a study probiotic namely Propionibacterium freudenreichii 
produced Short chain fatty acids in the culture media and caused the cell death of 
gastric and colon cancer cells in humans [52, 53].
2.5.8 Constipation
It is common problem among the older population. Several controlled studies 
showed that in constipation either the bowel movements are increased or there is 
decrease in the transit time through the gastro-intestinal tract, for this purpose 
probiotics are utilized in the treatment of constipation [54, 55]. The most frequently 
used laxative is lactulose which is also a probiotics is not affected by the disacchari-
dases of the humans and the microflora in the colon, bifidobacterium utilizes it as a 
substrate that breakdown it into the smaller subunits leading to the creation of the 
osmotic effect. However, larger controlled studies are needed in order to confirm 
the use of prebiotics and probiotics apart from lactulose [56, 57].
2.5.9 Immunomodulation
Probiotics are involved in the modulation of the immune responses, are anti-
inflammatory in nature and also have effect on humoral and cell regulated immu-
nity. Probiotics are thought to involve in secretion of the factors that are responsible 
for regulating the immunity. For example the factors secreted from the probiotic 
strain L. reuteri limit the gene expression that is dependent on NF-Κb which results 
in the decrease in cell growth and greater protein kinases activated by nitrogen 
which leads to the induction of apoptosis [58].
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Probiotics are present in greater quantity in fermented milks. During milk fer-
mentation, L. helveticus is able to produce factors that are involved in enhancing the 
expression of calcineurin which is involved in the formation of mast and goblet cells 
in the gastrointestinal tract of mouse [59]. The intake of probiotic strain VSL3 is 
involved in down regulation of such immune responses by decreasing the secretion 
of IL-8, regardless of the presence of the bacterial pathogen Salmonella dublin [60].
2.5.10 Helicobacter pylori
The most common and worst bacterial infection found in human is the 
Helicobacter pylori. It causes a number of diseases like peptic ulcers, chronic gastri-
tis, lymphoma, gastric adenocarcinoma and number of other diseases not related 
to gastrointestinal tract. Probiotics prevent the H. pylori infection by enhancing 
the immunoregulation functions that works as antagonistic to infection caused by 
H. pylori [61–63]. Many studies reported that H. pylori growth and gastritis infec-
tion can be minimized but the causative organism cannot be completely removed. 
It is noted that prebiotics plays their role for the suppression of H. pylori as well as 
they also enhance the efficacy of eradication therapy by stopping the side effects 
caused by antibiotics thus improving compliance [64]. saccharomyces boulardii is 
found helpful in reducing the symptoms of Helicobacter pylori.
2.5.11 Liver disease
2.5.11.1 Hepatic encephalopathy
By changing the microbiota count in the gut either by using probiotics or 
fermentable fiber has been related for the treatment of hepatic encephalopathy in 
experimental studies [65, 66]. This therapy works as it lowers the blood ammonia 
level due to inhabitation of bacteria that is acid resistant as well as not producing 
urease Further work on this approach is still under work [67].
2.5.11.2 Nonalcoholic fatty liver disease
Nonalcoholic steatohepatitis is a disease in which patients are not edict of alcohol 
but showing the systems of liver biopsy. Experiments on model rats suffering from 
fatty liver disease have been indicated that intestinal microbiota, bacterial endo-
toxin and tumor necrosis factor α modulate liver damage caused by alcohol. There is 
a perception that intestinal microbiota produces endogenous signals, which shows a 
pathologic role in nonalcoholic fatty liver disease, suggests a role for novel probiotic 
therapy in this not so uncommon condition [68, 69]. Recent studies have showed 
that nonalcoholic fatty liver disease is also thought to be linked with the dysbiosis 
of gut microbiota. By restoring and maintaining the gut microbiota, nonalcoholic 
fatty liver disease can be controlled. However extensive studies on the strains of gut 
microbiota and tests on various probiotics may be helpful in determining the use of 
specific probiotic for this disease [70].
2.5.12 Probiotics in infants health
Human milk defends infants from contagious diseases by several mechanisms. 
Human milk has various components that modulate the intestinal microbiota 
and bifidobacteria. These bacteria are the basic and significant constituent of the 
infants that are fed with human milk [71, 72]. Human milk can also minimize the 
incidence and harmful effects of inhabiting pathogens [73, 74]. Consequently, 
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it has been observed that a balanced increased in bifidobacterial concentration 
and reduction in enteric bacterial count and luminal factors of host may show a 
positive role in defending premature offspring and infants from diarrheal disease. 
Alteration of the intestinal microbiota by improving the prevalence of nonpatho-
genic bacteria is an effective method to attain a therapeutic treatment against 
enteric pathogens [75].
2.5.13 Urogenital infections and HIV
Various urinary tract infections like yeast vaginitis, Bacterial vaginosis and 
frequent urinary tract infections are major problems faced by the patients. In 
premenopausal women normal microflora consist of lactobacilli that protect host 
from infections but various patho-physiologic causes can results infection due to 
unstable microflora. A very few studies that reports the importance of probiotics 
for urogenital health [76, 77]. The awesome practices have reported that L. aci-
dophilus has positive effect in urogenital health. Promising studies showed evidence 
that probiotics are also important in preventing recurrent urinary tract infection in 
women [78]. The women suffering from human immunodeficiency virus infection, 
prevention of bacterial vaginosis is very important. Previous literature indicates 
that women that have improper balance of lactobacilli (vaginosis) are in a great risk 
of human immunodeficiency syndrome [79, 80]. Therefore an adequate level of 
lactobacilli and preventing bacterial vaginosis is a best method to reduce the risk of 
getting human immunodeficiency virus infection, gonorrhea and trichomoniasis. 
One of the recent study shown that a probiotic strain (Lactobacillus reuteri RC-14) 
specific for human vagina can give strong protection from virus that can reduce 
the transmission of sexual immunodeficiency virus infection. Still, further work 
is required to approve these results before the extensive use of probiotics for the 
treatment of these diseases can be suggested [81].
2.5.14 Breast cancer
Several studies have been conducted on animal and human models to check the 
effect of probiotics in breast cancer. Several in vitro studies have shown that probi-
otics are involved in reducing the tumor size and stopped the growth of tumour. In 
Human studies it was observed that the use of probiotic Lactobacillus casei shirota 
prevented the onset of breast cancer. Also the use of fermented dairy products such 
as yogurt and fermented milk was inversely linked with the onset of breast cancer. 
Probiotics can be used for both preventive and treatment purposes of breast cancer. 
However more studies are needed in order to confirm the safety and efficacy of 
probiotics in breast cancer [82].
2.5.15 Type 2 diabetes mellitus
Experiments have shown that Type 2 Diabetes Mellitus can be result of dysbiosis 
of gut microbiota. This microbiota is involved in the permeability of gut mucosa 
and immune system of host which are linked to the type 2 diabetes mellitus. 
Different type of probiotic strains either single or multiple can be used for interven-
ing type 2 diabetes mellitus. Probiotics that are mainly used to treat the symptoms 
of type 2 diabetes are Lactococcus, Bifidobacterium and Lactobacillus. After the 
oral probiotic administration can be helpful in modulating the immune function, 
gut microbiota and balancing the energy metabolism. Therefore it was suggested 
that probiotics are involved in reducing the incidence, delaying and reversing the 
complications of Type 2 diabetes [83].
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3. Meat and dairy products as a functional agent
3.1 Dairy Products
Authors have considered different traditional dairy products such as yogurt, 
milk and cheese as a functional products as these are rich source of various vitamins 
and minerals and other constituents that can be used as functional agents [84]. 
Such as conjugated linoleic acid (CLA) and Selenium, that play an important role in 
lowering the serum cholesterol level thus preventing the atherosclerosis and other 
cardiovascular diseases also having antioxidant functions in the body [85].
Yogurt is a traditional dairy product that was prescribed by physicians in Middle 
East as a treatment of gastrointestinal diseases [86]. Yogurt is manufactured 
using Streptococcus thermophilus and Lactobacillus bulgaricus which both work in 
synergism. Health benefits of yogurt can be enhanced by the addition of probiotic 
bacteria in yogurt such as Bifidobacterium, Lactobacillus acidophilus and L. rham-
nosus [87]. Yogurt has been used a food source consisting of probiotic organism 
throughout the world.
A wide variety of fermented milks have also been developed and various health 
benefits were linked with the consumption of fermented milks such as lowering of 
cholesterol. They also contain the important probiotics strains that are involved in 
improving the health [88].
Probiotic cheeses are available in soft as well as hard varieties. Various Probiotic 
Strains such as Bifidobacterium and L. rhamnosus are readily used in such cheeses 
and these cheeses can be beneficial source of Probiotics [89].
3.2 Meat products
Meat products are good source of protein and fat along with water and other 
vitamins which are highly bioavailable. Meat products can be made highly 
beneficial for health either by incorporating any ingredient in it that is consid-
ered healthy or eliminating or reducing any component that can be considered 
harmful [90].
Fatty acid and cholesterol level of meat can be modified by selecting different 
breeds, modifying the feed patterns, addition of some feed additives and several 
interventions regarding animal metabolism [91].
Similarly addition of olive oil to variety of meat products was thought to be 
associated with the high biological value and decrease onset of breast cancer and 
heart diseases [92].
Soy protein can also be added into the meat products. In 1999, US FDA stated 
that any product low in saturated fats and cholesterol containing 25 g of soy pro-
teins may be helpful in preventing the cardiovascular diseases [93].
Lipid oxidation is the major issue in meat products thus instead of using syn-
thetic antioxidants that pose toxicity and other harmful effects can be replaced 
by the antioxidants from the plat source such as rosemary, tea, etc. Green tea is 
associated with reducing the level of Cholesterol in body as well as increasing the 
portion of High density Lipoproteins and decreased the oxidation of lipoproteins 
[90, 94, 95].
Addition of salt for the preservation purpose can lead to high percentage of salt 
intake and can lead to the development of hypertension. Several substitutes were 
assessed and one of the best substitute was the addition of calcium ascorbate. This 
substitute causes higher acidification due to the fermentation by lactic acid bacteria. 
Replacement of salt with Calcium ascorbate helped in reducing the sodium chloride 
level as well enriching the meat with nutrition [96].
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4. Prebiotics
Prebiotics are the food that is not digested in the human gut but food ingredients 
boost the growth and activity of bacteria that are good for our intestine, conse-
quently they balance the intestine of an organism [97]. The most commonly used 
bacteria that are good for our health is amplified by prebiotics comprise of genus 
Bifidobacterium and Lactobacillus, which control the growth of harmful bacteria. 
Most commonly used prebiotics are mannan-oligosaccharides, galactoglucoman-
nans, lactose, inulin and oligofructose. Short chain carbohydrates used as prebiotics 
consist of three to ten sugar units derived from the cell wall of yeast and plants. 
Prebiotics functionality are not alter by any food processing treatment and require 
little or no regulatory requirements, hence making their consumption more easy as 
compare to chemical treatment.
4.1 Mode of action of prebiotics
Important modes of action of prebiotics are:
• These are non-digestible carbohydrates that are not digested by the upper gas-
trointestinal tract and travel in the ileum and colon where fermented by the 
resident microbes.
• Prebiotics do cause intestinal homeostasis.
• Host surface receptors are coated by prebiotics.
• They produce bateriocins.
• Favorable bacteria produce short chain fatty acids with the help of non- digestible 
carbohydrates.
• Short-chain fatty acids are the energy source of epithelial cells.
• They regulate metabolic function and modulate immune system [98].
4.2 Targets for prebiotics: gut microbiota and intestinal health
Fermentation of resistant starches and dietary fiber caused by bacteria in colon 
release short chain fatty acid metabolites (SCFA). SCFA are well known for gut 
health as well as their part in provision of supplementary energy to the host in 
fatness is in debate. On contrary, 10% of entire energy in humans is provided by 
SCFA. According to energy yield hypothesis, dysbioticmicrobiomes have an ampli-
fied capacity to remove energy from the food, so that the bacterial conversion of 
non-digestible carbohydrates and dietary fiber to SCFAs could give additional 
energy to the host and result fatness of individual over time. Likewise, G-protein 
coupled receptors (GPR) can sense SCFAs that tie them with lipid and glucose 
breakdown. SCFAs activate the two major proteins, GPR41 and GPR43 which are 
expressed on adipocytes and enter endocrine L cells. Peptide YY is released by 
stimulation of intestinal GPR41 which enhances gut passage time and increase sati-
ety. Inflammation lessens by activation of intestinal GPR43 as well as it simulates 
glucagon-like peptide (GLP), a hormone which contributes in regulation of insulin 
secretion. Enteroendocrine L cells express GLP-1 as well as secrete the gut-trophic 
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hormone GLP-2. Chief stimulus for GLP-2 secretion is nutrient consumption. 
SCFAs maintain the release of GLP-2 which is important in regulation of the gut 
fence system and decreases lipopolysaccharide translocation [99].
4.3 Healthy diet for probiotic
4.3.1 Dietary fiber
Diet is an element on which unequal antagonism exists between the microflora 
of gut and specific group of bacteria get their nutrition. It also serve as direct 
medium for the gut microflora since it may act as a direct substrate for the microbi-
ota through its indigestible constituents and some by-products of digestion. Among 
all the nutritional constituents, dietary fibers are vital as they cannot be absorbed in 
the upper part of the digestive system; although they can be fermented in the lower 
part of the gut by the intestinal microbiota [100].
4.3.2 Prebiotics
Prebiotics are a subcategory of nutritional fibers that is not affected by the 
gastric acidity and the enzymes present in the digestive system of mammals which 
is very crucial for our health [101]. The main distinguishing benefit of prebiotics 
is their stimulation in growth of intestinal bacteria connected with fitness and 
comfort [102].
4.3.3 Complex carbohydrate
Some complex carbohydrates include resistant starch and plant cell-wall poly-
saccharides are not digested by the gut microflora. Polysaccharides comprising of 
cellulose, hemicelluloses (xylan, xyloglucan, mannan, β-glucan) and pectin. These 
all complex carbohydrates have positive simulative effect on microbial populations 
in the gut [103]. A number of bacteria present in human gut that possess genes 
programming with carbohydrate-active enzymes (CAZymes) in their genomes. 
These bacteria can digest such compound carbohydrates.
4.3.4 Prebiotic carbohydrates
Prebiotics definition is fulfilled by resistant starch [101]. In the colon prebiotic 
type of fermentation is provided by it and has lots of metabolic advantages, for 
instance it increase the bile salt production and laxation, lowers the danger of 
gastrointestinal tract cancers, and lowers the after meal glucose stimulus and blood 
lipid levels [104, 105]. Farther more it assists in growing of epithelial cells and 
propagation by increased butyrate concentration via its fermentation by the gut 
microbiota [106].
4.3.5 Algal (AGAL) polysaccharides
AGAL polysaccharide provides with dietary fiber, e.g., alginates, agars and 
carrageenan from seaweeds, consumed in food industry as thickeners and stabiliz-
ers or emulsifiers [107]. Many health benefits provided by dietary fibers due to 
its gel-forming ability and other physicochemical properties, including ability to 
ferment by the alimentary canal microbiota [108]. These benefits include controlled 
appetite, type 2 diabetes and obesity by increasing satiation, refining of gut barrier 
working and lessening the ad worse effects of luminal components.
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Gut bacteria cause fermentation of compound carbohydrates that has ben-
eficial affect for the host. This activity makes complex carbohydrate as potential 
prebiotics. Proteolytic activity produce potential harmful product and the 
fermentation of complex carbohydrates reduce risk caused by these harmful 
metabolites [109]. Furthermore, some useful metabolites with anti-cancer and 
anti-inflammatory activities, like phenolic substances and short chain fatty acids 
are also produced by the microbial fermentation of complex carbohydrates in the 
gut [110].
Chemically, inulin-type fructans are a linear polydisperse carbohydrate 
material consisting mainly, if not exclusively, of β-(2–1)-fructosyl-fructose gly-
cosidic bond linkages [81]. Fructans are proposed to be classified as “functional 
fiber” according to recent concepts drawn from physiological effects on human 
individuals [111].
Guar galactomannan was enzymatically hydrolyzed to obtain partially hydro-
lyzed guar gum which can be utilized as prebiotic source. Partially hydrolyzed guar 
can be considered as potential prebiotic compound that may further stimulate the 
growth of potentially probiotic bacteria or native gut microflora [112].
4.3.6 Herbal prebiotics
Some herbs are used for the treatment of inflammatory immune diseases that 
also have prebiotic effect in the host. These herbs include Ocimum sanctum, Piper 
nigrum and Zingiber officinale. Zingiber officinale and Ocimum sanctum exhibited 
greater prebiotic activity, with higher growth of Lactobacillus and Bifidobacterium 
as compare to most commonly used prebiotic, fructo-oligosaccharide (FOS). 
However, Piper nigrum have similar prebiotic activity as that of most commonly 
used prebiotic FOS. These herbs used to regulate gut microbiota which ultimately 
prevent systemic swelling and related disorders [113].
4.3.7 Fractionated lotus seed resistance starch
Fractionated lotus seed resistance starch (LRS3) was fractionated and tested for 
its structural properties and prebiotic activities. LRS3–20% showed higher pre-
biotic activity against these bacteria Bifidobacterium adolescentis and Lactobacillus 
acidophilus as compared to LRS3–30% and high concentration of amylose maize 
starch [114].
4.3.8 Cereal grain fraction
Most commonly used cereal grains to develop new classes of prebiotic are corn, 
rice, wheat, barley and oats which also have high economic value [115].
4.3.9 Burdock root
It is rich source of fructo-oligosaccharides and phenolic compound but its use 
in food products are limited. It is widely used in bakery product for consumers that 
search for functional foods of health benefits. Burdock roots are effective alterna-
tive for functional foods with health benefits [116].
4.3.10 Lentil
Lentil food are rich source of prebiotic carbohydrates which have raffinose fam-
ily oligosaccharides, fructooligosaccharides, sugar alcohols and resistance starch.
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4.4 Therapeutic potential of prebiotics
4.4.1 Prebiotic impact on intestinal micro flora
Dietary fibers which are part of prebiotic play positive impact on intestinal micro 
flora [117]. In cholesterol metabolism prebiotic fibers play a very unique action specifi-
cally on fermentation of products and modulation of micro flora. Some research show 
both probiotics and prebiotics (in which non digestible food ingredients are more benefi-
cial for host which stimulate the growth of colonic bacteria) to suppress tumor and pre-
neoplastic lesions in the colons of animal treated with carcinogenic chemicals [118]. The 
presence of beneficial bacteria in gut of infants fed with human breast milk is supported 
by the metabolism of the complex mixture of oligo saccharides present in the milk. More 
mature gut microbiota is found in the formula milk. In adults formulation infants is used 
to achieve a type of intestinal microbiota. Improper gut microbiota (dysbiosis) can cause 
autoimmune disorders, infections and allergic reactions in old age [59].
4.4.2 Colon cancer and prebiotics
Aberrant crypt foci (ACF) is the first detectable abnormal growth of cells 
appears as lesions in the large intestine. To identify ACF lesions chromoscopic 
colonoscopy of high magnification is used, generally it appear as colonic mucosa. 
They comprised of crypts that are raised on upper side of normal mucosa. It 
consists of extremely condensed epithelia and has changed luminal openings visibly 
confined from the normal neighboring crypts. The development of the ACF to 
polyp, adenoma and adenocarcinoma equivalents buildup of numerous genetic and 
biochemical modifications. A little amount of ACF can be a cause of colon cancer. 
Presently, it is unidentified that which crypts are responsible for the development 
of tumor. Though, various researches support the idea of development of colon 
cancer from ACF [119]. Perrin et al. [120] reported that some fibers which stimulate 
the formation of stable butyrate-producing colonic ecosystem. This type of colonic 
environment diminished the rate of ACF. Therefore it is clear that colonic ecosystem 
that produces stable butyrate decreases the risks of developing colon cancer.
4.4.3 Prebiotics modulation of immune function
Immunological functions are modulated by our diet and affect resistance of host 
by various ways. Along with essential food components non-essential nutrients like 
non-digested carbohydrates also play an important role in controlling the immuno-
logical responses, particularly lymphoid tissues of the gut. Bodera [121] reviewed 
the previous literature by various scientist on the effects of prebiotics in enhancing 
the immunity of host and observed that there is sufficient proof indicating prebiot-
ics such as inulin helps in the modulation of immunological functions. He suggests 
to take prebiotics for the modulation of immunological parameters in gut associated 
lymphoid tissues, secondary lymphoid tissues and peripheral circulation. First line 
defense is provided by the innate immune system and prevent the entry of conta-
gious agents or eradicating entering pathogens. It encompasses physical fences like 
skin and mucous membranes, blood cells and tissue, such as phagocytes, natural 
killer cells and soluble mediators, like supplement proteins and cytokines.
4.4.4 Prebiotics as dietary modulators of gut microbiota in obesity
It is suggested that gut microbiota plays an important role in obesity and obesity-
associated comorbidities that gut microbiota could be a possible goal for fatness 
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involvements. It is assumed that microbial dysbiosis is associated with fatness, it 
is concluded that restoring the potential symbiosis between the gut microbiota 
and host holds great potential. Prebiotics are consumed so that gut microbiota can 
be modified. Prebiotics are not capable to be digested by host enzymes although 
they move in the large intestine and are particularly fermented in the gastrointes-
tinal tract where they help in growth of bacteria particularly Bifidobacterium and 
Lactobacillus that have been related with health benefits [122].
4.4.5 Prebiotics assist in the management of cognition
Worldwide, Schizophrenia is the 25 leading cause of disabilities that decrease 
the life about 10–20 years. Inappropriate treatment like pharmacotherapy in the 
administration of cognitive defects and weight gain are recognized a significant 
contributors of these diseases; therefore there is a need to develop such treatments 
that alleviate one, or both, of these diseases would be very helpful. By using gut 
microbiome from dietary source like prebiotics for the treatment of these diseases 
may be one such intervention. Moreover, prebiotics also effect breakdown, and 
in case of obesity they rise the concentration of anorexigenic gut hormones such 
as peptide tyrosine tyrosine, glucagon-like peptide 1 and leptin and decrease the 
amount of orexigenic hormones such as ghrelin [123].
4.4.6 Prebiotics for the improvement of enzyme activity and phosphate uptake
Prebiotics improve the activity of enzymes and phosphate uptake in the intes-
tine. One of study was conducted to recognize the impact of prebiotics supple-
mentation in infant formula on enzyme activity and phosphate uptake in the small 
intestine of Sprague Dawley (SD) rats. Forty-eight fifteen days old SD rats of similar 
weight were divided into three groups randomly: A was selected as control group in 
which SD rats were fed with standard infant formula with no prebiotics treatment. 
Rats in groups B, C were nourished standard infant formula supplemented with 
oligosaccharides, and the standard infant formula supplemented with polysac-
charides, correspondingly. The results were checked at 28 days. It was observed that 
as compared to group A, group B and C showed the following: (1) In SD rats group 
C showed greater activities of sucrose and lactase in the small intestine; (2) In SD 
rats of group C comparative expressions of lactase gene in the anterior and posterior 
segments of the small intestine were increased by 1.68 and 2.26, and the Mgam gene 
relative expression in the posterior segment of the small intestine was improved 
by 0.99 in SD rats of group C; (3) the relative expressions of Na/Pi-IIb gene in 
the anterior and posterior segments of the small intestine were increased by 1.85 
and 2.28 in SD rats of group C. These results specify that the supplementation of 
prebiotics in infant formula can stimulate enzyme movement in the small intestine 
by improving the relative expression of enzyme gene and Na/Pi-IIb gene and by 
reducing the intestinal injury. The polysaccharides improved to be healthier than 
that of oligosaccharides [124].
4.4.7 Prebiotics and the bioavailability of minerals and trace elements
Prebiotic carbohydrates have positive influence in the absorption of minerals 
and trace elements. There exist a promising evidence about the stimulatory impact 
of prebiotic carbohydrates (non-digestible oligosaccharides and lactulose) on the 
bioavailability of minerals and trace elements. However, most of the studies is on the 
rats because, the studies on the human is limited. It has been hypothesized that pre-
biotics create strong osmotic effect that reduce the pH and stimulate the exchange of 
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protons and increase level of calbindin and butyrate. Colon surface area also enlarged 
that is a good source to increase the minerals and trace elements absorption [125].
4.4.8 Prebiotics in diabetes and cardiovascular diseases
Prediabetes is linked with the long term inflammation that is associated with 
greater risk of developing type 2 diabetes and cardiovascular diseases. Increased con-
centration of lipopolysaccharides is linked with dysbiosis of the natural microbiota 
that is involved in the development of type 2 diabetes and cardiovascular diseases. 
Prebiotics involved in the selective functioning of natural micro biota such as inulin 
decreases the concentration of endotoxin, reduces permeability of the intestines and 
limit the metabolic dysfunction in rodents. The impact of prebiotics on the cardio-
vascular functions in patients at the risk of type 2 diabetes is still unknown. The 
prebiotic supplementation along with inulin could be used as preventive strategy for 
limiting the risk of cardiovascular diseases in the patients at risk of type 2 diabetes. 
This strategy can affect the clinical practices by setting and accepting dietary recom-
mendation of prebiotics by medical and scientific community [126].
4.4.9 Prebiotics and renal profile
It is well documented that prebiotics, probiotics and the symbiotic supplementa-
tion had resulted in the improvement of renal function. Firouzi and Haghighatdoost 
[127] studied renal profile of a meta-analysis of a clinical trial. They pointed out that 
level of glomerular filtration rate was reduced whereas the concentration of creatinine 
was increased in the intervention group in comparison to the placebo group and the 
results were non-significant. The combined effect on the blood urea nitrogen demon-
strated that the level declined as compared to the placebo group. Whereas the levels of 
uric acid increased in intervention group in comparison with the placebo group. The 
supplementation of prebiotics, probiotics and symbiotic should be limited among 
those in which renal function is compromised until well designed and large scale 
randomized controlled trials prove the efficiency and safety of prebiotics, probiotics 
and symbiotic supplementation for having improved effects on the renal function.
4.4.10 Prebiotics in controlling cancer
A study was conducted to check the impact of prebiotics intake consisting of 
xylo-oligosaccharides, fructo-oligosaccharides, resistant dextrin and polydextrose 
on immunity and the structure of gut microbiota in perioperative colorectal cancer 
patients.
A double blind, randomized clinical trial was conducted that consisted of 140 
perioperative colorectal cancer patients involving 50 females and 90 males having 
age between 40 and 75 years. Patients were divided on random basis into two groups 
consisting of intervention group that received 30 g/day of prebiotic supplementa-
tion for the period of 7 days and control group that did not receive supplementa-
tion. The immunological and nutritional indices of both groups were evaluated 
before and after operation and were compared with their baseline levels. Also the 
fecal samples of random 40 patients from the both groups were taken to examine 
the gut microbiota. There was significant reduction in the abundance of intestinal 
microbiata from pre to post operation in the control group. Intake of prebiotics 
is recommended to improve immunological indices in patient having colorectal 
cancer for 7 days before operation. Prebiotics enhanced the concentration of four 
commensal microorganism containing opportunistic pathogens in patients having 
colorectal cancer. Surgical stress decreased the population of intestinal microbiota 
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but increased the population of commensal microbiota and opportunistic microor-
ganisms. For further research Bacteroides is considered as a relevant bacterial species 
on the mechanism of prebiotics [128].
4.4.11 Anxiolytic effect of prebiotics
Long term treatment of prebiotics particularly combination of fructooligosac-
charides and galactooligosaccharides have antidepressant effects and also involved 
in combating the issues related to anxiety. The effect of Galactooligosaccharide 
(GOS) and the combination of fructooligosaccharides and galactooligosaccharides 
is involved in reducing the level of corticosterone level in the body by mainly 
limiting its release. Prebiotics are involved in modifying the expression of specific 
genes related to the concentration of short chain fatty acids in the hypothalamus 
and hippocampus. Administration of Prebiotics resulted in the increased level of 
acetate and propionate and reduction in the concentration of isobutyrate that have 
significant correlation with the positive effects on behavior. Moreover, the admin-
istration fructooligosaccharides and galactooligosaccharides reduced the level of 
corticosterone and proinflammatory cytokines resulted from the chronic stress as 
well as normalizing the anxiety and depression like behavior along with mitigating 
the impact of stress on the microbiota [129].
5. Conclusion
Probiotics and prebiotics are functional foods that have significant biotechno-
logical benefits with wonderful potential for invention. Though probiotics and pre-
biotics are likely to be used in treating many communicable and non-communicable 
disorders but it is very hard to draw conclusions from a number of researches that 
indicating the therapeutic potential of probiotics and prebiotics because scientists 
used different strains and prescriptions for various disorders. Further research 
using reliable regulations will permit more decisive results on the effects of probiot-
ics and prebiotics for treatment of various diseases. Although various products with 
probiotic, prebiotics and symbiotic are usually available in food and supplement 
formats, in near future these products will target to specific disease and will be 
available as drug.
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